

**Maryland Board of Pharmacy
Public Board Meeting**

**Meeting Minutes
December 16, 2020**

Name	Title	Present	Absent
Bouyoukas, S.	Commissioner	X	
Evans, K.	Commissioner	X	
Fink, K.	Commissioner	X	
Glascoc Geigher, P.	Commissioner	X	
Hardesty, J.	Commissioner/Treasurer	X	
Leikach, N.	Commissioner	X	
Morgan, K.	Commissioner/President	X	
Oliver, B.	Commissioner	X	
Rusinko, K.	Commissioner/Secretary	X	
Singal, S.	Commissioner	X	
Yankellow, E.	Commissioner	X	
Bethman, L.	Board Counsel	X	
Felter, B.	Staff Attorney	X	
Speights-Napata, D.	Executive Director	X	
Fields, E.	Deputy Director of Operations	X	
James, D.	Licensing Manager	X	
Leak, T.	Compliance Director	X	
Clark, B.	Legislative Liaison	X	
Chew, C.	Enforcement Compliance Auditor	X	

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
<p>II. A. Executive Director Report</p>	<p>D. Speights-Napata, Executive Director</p>	<p>1. Upcoming Meetings</p>	<p>1a. Interviews for the Director of Provider Engagement and Regulation with the Maryland Department of Health will take place in a few weeks. This agency includes PDMP and the office of Controlled Substances. Ms. Speights-Napata will be on the interview panel.</p> <p>1b. She will be in attendance at the MSHIP winter meeting; their annual meeting will be virtual more information will be forthcoming.</p> <p>1c. Ms. Speights-Napata participated in the bi-weekly Baltimore City Mass Vaccination Workgroup along with other agency representation from Baltimore City government and state officials that participate in the COVID-19 mass vaccination efforts. There were topics of discussion, such as long term care facility outreach; all facilities have been signed up for the federal pharmacy vaccination program. There are currently over 400 long term care facilities in Baltimore. The start date is TBD, once the state makes a request it will take</p>	

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
			<p>about 2 weeks for implementation.</p> <p>1d. Logistics for the Baltimore City Health Department planning has taken place, there are two city sites identified for initial vaccine administration. The initial plan for targeting points of dispensing has been created, that includes floorplans, staffing model, supplies and identifying staff. The initial will run for 5 days over 200 doses in a single day with the Pfizer vaccine staffing needs will consist of 40 per location. The local COVID-19 vaccination plan is currently under development.</p> <p>1e. The Prioritization algorithm is still being determined by federal and state authority. This will have a large impact on local strategies and operational plans, more information will be provided once it's received.</p> <p>1f. Ms. Speights-Napata participated in the weekly NABP executive director meeting; these meetings are scheduled on an as needed basis. Dr. Jeanie Santoli with CDC provided an update on the</p>	

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p style="text-align: center;">2. Staffing Update</p>	<p>COVID-19 vaccination plan. McKesson will be used for Moderna and they are supplying a minimum of 100 doses. There are states such as Virginia and Nevada are seeking Emergency waivers to allow external storage units outside of the pharmacy at a nearby clinic or health department to house the vaccination. The Board have received a similar request here in Maryland and it will be discussed in our committee process. More information will be provided as soon as it's received.</p> <p>2a. Nancy Richard, Pharmacy Inspector will be recertifying her sterile compounding training through Critical Point. Roehen Wang, Investigator Supervisor and Nancy Richard have been accepted into MDH Leadership Program, the training is about 4 months and will be virtual. Ike Acheampong and Jered Pasay participated in the FDA virtual training. Ike will also be participating in the Clear Point certification training for inspectors and investigators. Ms. Speights-Napata provides time for staff to stay trained it's</p>	

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>an essential part of staff development.</p> <p>2b. Brad Clark, Legislative Liaison will be leaving the Board; he has accepted a position with the Harford County public defender's office. The Board wishes him well in the new position. The Board will be seeking another intern from the University of Baltimore Law School.</p> <p>3. The Acute Care seat on the Board is available we have received 2 applications thus far Please visit the Board's website on how to apply.</p> <p>4. An email blast from the Board was distributed seeking volunteers for Maryland Responds; it yielded over 300 responses. Please contact Maryland Responds directly for more information.</p> <p>5. Commissioner Leikach was interviewed and is highlighted in the NABP Innovations magazine.</p> <p>6. The Board received a few complaints of fraudulent phone calls and emails. Please report these issues to the Board via</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
B. New Business	K. Morgan, Board President	<ul style="list-style-type: none"> President Morgan attended the PDMP advisory board replacing Commissioner Dan Ashby. They welcomed President Morgan, Peggy Funk-Executive Director of Hospice & Palliative Care Network-of Maryland and Joseph Mattingly-of University of Maryland School of Pharmacy to the Board. Topics of discussion included communication with providers in Maryland ensuring PDMP continue to work with providers in order to share crucial information to them. Another topic surrounded veterinary registration and dispensing. Pharmacist and licensed practitioners share concerns of registration-this may come to our Board at some moment. There was a question regarding pet entry in our dispensing systems. President Morgan and Board Counsel Linda Bethman encouraged pharmacists to provide any information on clinical user interface-can it be customized per user for a quicker informative decision making experience. President Morgan welcomes emails to him with discussion topics for 2021 to take back to PDMP Advisory Board. 	phone 410-764-4755 or email mdh.mdbop@marland.gov	

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results																														
C. Operations Report	E. Fields, Deputy Director/Operations	<p>1. Procurement and Budget Updates</p> <p>a. November 2020 Financial Statements</p> <p>2. Management Information Systems (MIS) Unit Updates</p>	<p>1a. A report on board revenue for November was provided.</p> <p>2. There are 448 pharmacists, 1,102 technicians and 74 pharmacies that did not renew their license, registration or permits between March-November; due to the Governors Executive Order for the COVID-19 pandemic.</p>																															
D. Licensing	S. Bouyoukas, Commissioner	<p>1. Unit Updates</p> <p>2. Monthly Statistics</p> <table border="1" data-bbox="873 869 1396 1474"> <thead> <tr> <th>License Type</th> <th>New</th> <th>Renewed</th> <th>Reinstated</th> <th>Total</th> </tr> </thead> <tbody> <tr> <td>Distributor</td> <td>13</td> <td>1</td> <td>0</td> <td>1,444</td> </tr> <tr> <td>Pharmacy</td> <td>17</td> <td>0</td> <td>0</td> <td>2,109</td> </tr> <tr> <td>Pharmacist</td> <td>51</td> <td>508</td> <td>0</td> <td>13,013</td> </tr> <tr> <td>Vaccination</td> <td>50</td> <td>151</td> <td>0</td> <td>5,047</td> </tr> <tr> <td>Pharmacy Intern - Graduate</td> <td>2</td> <td>0</td> <td>0</td> <td>59</td> </tr> </tbody> </table>	License Type	New	Renewed	Reinstated	Total	Distributor	13	1	0	1,444	Pharmacy	17	0	0	2,109	Pharmacist	51	508	0	13,013	Vaccination	50	151	0	5,047	Pharmacy Intern - Graduate	2	0	0	59		
License Type	New	Renewed	Reinstated	Total																														
Distributor	13	1	0	1,444																														
Pharmacy	17	0	0	2,109																														
Pharmacist	51	508	0	13,013																														
Vaccination	50	151	0	5,047																														
Pharmacy Intern - Graduate	2	0	0	59																														

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results																				
D. Compliance	T. Leak, Compliance Director	<table border="1"> <tr> <td>Pharmacy Intern - Students</td> <td>14</td> <td>10</td> <td>0</td> <td>769</td> </tr> <tr> <td>Pharmacy Technician</td> <td>78</td> <td>311</td> <td>1</td> <td>10,794</td> </tr> <tr> <td>Pharmacy Technician Student</td> <td>3</td> <td>0</td> <td>0</td> <td>32</td> </tr> <tr> <td>TOTAL</td> <td>228</td> <td>981</td> <td>1</td> <td>33,267</td> </tr> </table>	Pharmacy Intern - Students	14	10	0	769	Pharmacy Technician	78	311	1	10,794	Pharmacy Technician Student	3	0	0	32	TOTAL	228	981	1	33,267		
Pharmacy Intern - Students	14	10	0	769																				
Pharmacy Technician	78	311	1	10,794																				
Pharmacy Technician Student	3	0	0	32																				
TOTAL	228	981	1	33,267																				
		<p>1. Unit Updates</p> <p>2. Monthly Statistics</p> <p>Complaints & Investigations:</p> <p>New Complaints –15</p> <ul style="list-style-type: none"> • Customer Service –1 • FDA Warning Letter, USP 797/cGMP Violations – 2 • Disciplinary Action in Another State –1 • Unprofessional Conduct – 1 • Refusal to Fill– 1 • Medication Error– 2 • NABP VPP Compounding Issues –3 • Inspection Issues –3 • Fraud –1 • Inspection Issues –6 • Resolved (Including Carryover) –16 • Actions within Goal –9/16 • Final disciplinary actions taken –0 																						

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<ul style="list-style-type: none"> • Summary Actions Taken –0 • Average days to complete –630 <p>Inspections: Total – 146 Annual Inspections – 74 annual and 59 Narcotic Audit (follow-up) inspections Opening Inspections – 10 Closing inspections – 1 Relocation/Change of Ownership Inspections – 1 Board Special Investigation Inspections – 1</p>		
E. Legislation & Regulations	B. Clark, Legislative Liaison	<p><u>Regulations</u> NONE</p> <p><u>Legislation</u> NONE</p>		
III. Committee Reports A. Practice Committee	K. Evans, Commissioner	<p>Kathleen Cook: I have a quick question in regards to the law about pre- printed prescription pads.</p> <p>The law states: A prescription for a controlled dangerous substance within the meaning of Article 27 of the Code, may not be written on a preprinted prescription form that states the name, quantity, or strength of the controlled dangerous substance. Annotated Code of Maryland, Health-General Article, Title 21-220.</p> <p>Preprinted prescription pads for non-controlled dangerous substances are not prohibited by law</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>Is this the same for a pre-stamped prescription as well? I have attached a photo of the prescriber in question to verify if it is valid or not.</p> <p>Proposed Response: A pre-stamped prescription is considered a preprinted prescription as that term is used in Md. Code Ann., Health Gen. § 21-220(b). by the Board of Pharmacy and the Maryland Office of Controlled Substances Administration. For further information please contact OCSA at maryland.ocsa@maryland.gov.</p> <p>Mike Burns-InstyMeds: The Board of Physicians has indicated that dispensing of medication by a physician is under their oversight and jurisdiction.</p> <p>I am reaching out to the Board of Pharmacy to ensure that if a client of ours is proposing to implement an InstyMeds Medication Adherence System (IM-MAS) in their hospital ER that we need to work with the Board of Physicians?</p> <p>The system functions within the physicians dispensing model, and is not a vending machine because it is used by patients upon invitation only.</p> <p>Integrates the best of pharmacy practice into physician dispensing. Accuracy has been tested and confirmed.</p> <p>InstyMeds has been in business since 2000, and successfully operating in many states.</p> <p>Proposed Response: If the drugs are being purchased, stocked and dispensed from the machine under a physician's license, the Board of Physicians' regulations govern the transaction. Please note, however, that utilizing the physician dispensing model,</p>	<p>Recommendation by committee to approve draft response; 2nd by K. Morgan.</p>	<p>The Board voted to approve this motion.</p>
			<p>Recommendation by committee to approve draft response; 2nd by K. Morgan.</p>	<p>The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>the hospital pharmacy does not stock or have any oversight over the units.</p> <p>Kenneth Erickson - MedStar Union Memorial Hospital KARLA EVANS RECUSED</p> <p>I am requesting clarification or guidance regarding a proposed process change for dispensing of kits/trays that have been processed using our Kit Check RFID tag solution.</p> <p>This solution requires a Pharmacist to verify each RFID tag, attached to a product, is encoded with the correct medication, concentration, NDC, Lot#, and expiration date.</p> <p>The RFID scanning station then reads these Pharmacist verified products with tags to confirm that each kit or tray contains the correct medication and quantities AND that each of these products are in date and not subject to a recall.</p> <p>Only when the verified products in the kit/tray meet all requirements will the kit/tray be successfully completed and made available for dispensing.</p> <p>Our current process is to have a Pharmacist encode/verify medication stock to be used in our kits/trays for scanning by the Kit Check RFID scanning solution, have our technicians fill the kits/trays with this verified stock of medications, process the tray and receive a notice of completion when all Kit Contents meet the required needs of the kit/tray and are not expired or being recalled, and then the Pharmacist manually checks the kit/tray again and signs the printed</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>notice of completion so the kit/tray is able to be dispense.</p> <p>Our findings: Because the pharmacist is responsible for the encoding and verifying of the products used with this technology solution, no product is dispensed that has not been previously verified by a pharmacist. When the pharmacists manually check these kits/trays after the RFID scanning has indicated a complete and expired med free kit/tray - they have found no incident of errors and kits/trays are signed off 100% of the time.</p> <p>Our request: When a successful kit/tray scan has occurred and a notice of completion is printed, we are asking that a technician is able to sign the completed kit/tray form and allow it to be dispensed without having a pharmacist manually check these again. Since all the stock has already been checked and verified by a pharmacist and the technology solution does not allow any kit/tray to be completed if there re expired or wrong meds present, we would like to have pharmacist focus on other tasks that need and require their attention.</p> <p>Proposed Response: In the situation that you have described, a final check by a pharmacist would still be required (see COMAR 10.34.34.03A(8)). Please note, however, that the Board is currently engaged in discussions of expanding its regulatory framework to allow for similar processes that will allow for technicians to perform non-clinical tasks as you have described.</p> <p>Wee Phung: Please allow me to describe a scenario, then ask you a question:</p>	<p>Recommendation by committee to approve draft response; 2nd by K. Morgan.</p>	<p>The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>A Maryland-licensed non-resident pharmacy is practicing strict social distancing per CDC guidelines. At the beginning of the Covid-19 period, the Maryland-licensed pharmacist of the nonresident pharmacy chose not to come to work in the pharmacy to supervise the dispensing and other daily pharmacy operations, because he lives with a high-risk family member. However, he counsels patients on their prescriptions via a HIPAA-secured phone and computer system in his home. The nonresident pharmacy does not have another Maryland-licensed pharmacist on staff.</p> <p>Since the Maryland-licensed pharmacist is not onsite, may the resident state-licensed PIC temporarily assume PIC duties for Maryland during this public health emergency period, and if so, should she send a notification to the board? If not, do you have other advice to give?</p> <p>I would appreciate you referencing legislature sections in your answers.</p> <p>Proposed Response: Maryland regulation 10.34.37.04B(2) requires that the Maryland-licensed pharmacist on staff at a nonresident pharmacy and designated as responsible for pharmaceutical care provided to Maryland patients must be regularly available on-site “as-needed” to provide care for Maryland patients. What constitutes “as-needed” is left to the professional judgment of the pharmacy and the Maryland pharmacist. Please note, however, that the designated Maryland pharmacist remains <i>responsible</i> for all pharmaceutical care provided to Maryland patients by the pharmacy, regardless of whether the designated pharmacist personally provided the care to the patient.</p>	<p>Recommendation by committee to approve draft response; 2nd by K. Morgan</p>	<p>The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p><u>Michael F. Conti, Maryland State Board of Nursing</u>: I have a client that will be completing her course of study to be a nurse practitioner in December. She is currently licensed as an RN in Maryland.</p> <p>After graduation as a nurse practitioner, she would like to open a business where she would give IVs that consist of non-prescription drugs like vitamin C, B12, and saline.</p> <p>I've reviewed the COMAR for a nurse practitioner's scope of practice and the text of House Bill 999 and Senate Bill 723 (2015) and have a few questions:</p> <ol style="list-style-type: none"> 1. COMAR 10.27.07.02(B)(7) states that an applicant for certification as a nurse practitioner has not been certified by the Board or any other Board of Nursing must designate a mentor for 18 months. Does this mean that if an applicant for certification as a nurse practitioner has been a registered nurse in Maryland the applicant does not have to designate a mentor? Or do all nurse practitioner applicants that are applying for the first time ever to be certified as a nurse practitioner in Maryland have to designate a mentor, regardless of whether they have been an RN? 2. Can a nurse practitioner delegate to a RN or LPN the tasks of preparing and administering an IV to a person that contains vitamins such as vitamin C or B12? What type of supervision level does a nurse practitioner have to provide to an RN if delegating any type of task? 3. Can an RN implement standard protocols that have been developed by a nurse practitioner, for example, a nurse practitioner develops protocols for when vitamin C is delivered to a person by IV - can an RN carry out those protocols without supervision? 		

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>Proposed Response: The Board of Pharmacy does not have any jurisdiction over the practice of a nurse practitioner; however, in the practice of pharmacy, the practice that you have described would be considered infusion therapy (see COMAR 10.27.20.02B(14)).</p> <p>Stephanie Oster-Medstal Health: If we were to find that we need to close some of our locations temporarily due to staffing shortages from COVID-19 is that something the BOP allows and what are the requirements to do so?</p> <p>We are trying to figure out if this is something we may need to look at for our chain. My main questions are around the notification piece as well as what happens with the current inventory in the pharmacy that may temporarily close?</p> <p>KARLA EVANS RECUSED</p> <p>PLEASE NOTE THAT THIS QUESTION IS A HYPOTHETICAL QUESTION AND DOES NOT REFLECT AN IMMEDIATE NEED TO CLOSE BY THE PHARMACY IN QUESTION.</p> <p>Proposed Response: Please see the Board's <u>March 17 guidance</u> regarding closures and changes to hours of operation during the COVID-19 pandemic. The Board will not enforce the 30-day notice requirement during the state of emergency; rather, the Board requires that pharmacies provide advance notice as soon as practicable if an establishment location is forced to change its hours or temporarily close.</p> <p>With respect to your question about inventory, the outcome will need to be determined on a case-by-case basis, dependent on the facts of the situation.</p>	<p>Recommendation by committee to approve draft response; 2nd by K. Morgan.</p>	<p>The Board voted to approve this motion.</p>
			<p>Recommendation by committee to approve draft response; 2nd by K. Morgan</p>	<p>The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
B. Licensing Committee	K. Rusinko, Commissioner	<p>1. Review of Pharmacist Applications:</p> <p>a. #124987 - Applicant is requesting an extension of her BOP application. COVID has forced her to reschedule her exams. <u>Committee recommendation: Deny extension, applicant is welcomed to reapply when application expires.</u></p> <p>b. #123883 - Applicant is requesting an extension of her MPJE and NAPLEX eligibility. Her ability to sit for the exams has been affected by COVID closures and preparing for the exams have been hindered by health complications. <u>Committee recommendation: Approve extension for 6 months, must reapply.</u></p> <p>c. #119808 - The Board has received a request from NABP to approve for the applicant to retake the NAPLEX exam for an 11th attempt. <u>Committee recommendation: Approve, must reapply if application expires.</u></p> <p>d. #127621 - Applicant is requesting an extension of the expiration date of her NAPLEX score. <u>Committee recommendation: Approve extension for 6 months.</u></p>	<p>1a. Recommendation by Committee to deny; 2nd by K. Morgan.</p> <p>1b. Recommendation by Committee to approve 6-month extension, must reapply; 2nd by K. Morgan.</p> <p>1c. Recommendation by Committee to approve -must reapply with the Board; 2nd by K. Morgan.</p> <p>1d. Recommendation by Committee to approve 6-month extension; 2nd by K. Morgan.</p>	<p>The Board voted to approve this motion.</p> <p>The Board voted to approve this motion.</p> <p>The Board voted to approve this motion.</p> <p>The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>e. #125002 - Applicant is requesting for approval to take the MPJE for an eighth time. <u>Committee recommendation: Approve, will need to reapply after March.</u></p> <p>f. #123951 - Reciprocity applicant is requesting an extension of his MPJE eligibility for a few months due to the current circumstances. <u>Committee recommendation: Approve extension for 6 months, will need to reapply.</u></p> <p>g. #127088 - Applicant is requesting approval to take the MPJE for a 6th attempt. <u>Committee recommendation: Approve.</u></p> <p>h. #122015 - Applicant is requesting extension of Board application and NAPLEX score. NAPLEX score expires 12/03/2020 <u>Committee recommendation: Approve score extension for 6 months, must reapply.</u></p> <p>2. Review of Pharmacy Intern Applications: NONE</p> <p>3. Review of Pharmacy Technician Applications: NONE</p> <p>4. Review of Distributor Applications: NONE</p>	<p>i.e. Recommendation by Committee to approve must reapply; 2nd by K. Morgan.</p> <p>1f. Recommendation by Committee to approve extension, must reapply; 2nd by K. Morgan.</p> <p>1g. Recommendation by Committee to approve; 2nd by K. Morgan.</p> <p>1h. Recommendation by Committee to approve 6-month extension; 2nd by K. Morgan.</p>	<p>The Board voted to approve this motion.</p> <p>The Board voted to approve this motion.</p> <p>The Board voted to approve this motion.</p> <p>The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>5. Review of Pharmacy Applications: NONE</p> <p>6. Review of Pharmacy Technicians Training Programs: NONE</p> <p>7. CE Approval Requests:</p> <p>a. MBF 1, MBF 2, MBF 3, MBF 4, MBF 5, MBF 6, MBF 7, MBF 8, MBF 9 - 10th Annual Pain Care Skills Training. <u>Committee recommendation: Approve for 15 hours.</u></p> <p>8. New Business:</p> <p>a. SS - Technician in training is requesting an extension due to COVID 19 of the 6-month registration requirement to complete the 160 hours. <u>Committee recommendation: Extend for 3 months.</u></p> <p>b. Steve Siegel /Best Pet Rx - Company is requesting approval to use the Virginia Board of Pharmacy inspection report in lieu of submitting a VPP inspection. <u>Committee recommendation: Will accept the VA Board of Pharmacy inspection.</u></p> <p>c. Bonnie Scott - Is a contract manufacturer that does not distribute into Maryland required to have a permit?</p>	<p>7a. Recommendation by committee to approve 15hrs; 2nd by K. Morgan.</p> <p>8a. Recommendation by committee to extend 3-months; 2nd by K. Morgan.</p> <p>8b. Recommendation by committee to accept VA inspection report; 2nd by K. Morgan.</p> <p>8c. Recommendation by committee; 2nd by K. Morgan</p>	<p>The Board voted to approve this motion.</p> <p>The Board voted to approve this motion.</p> <p>The Board voted to approve this motion.</p> <p>The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>Tabled from November 2020 Board Meeting</p> <p><u>Committee recommendation: When Company A holds the FDA marketing authorization for the drug, then it would need a permit in Maryland. When Company A's customer hold the FDA marketing authorization, then Company A does not need a permit as long as they are not a part of distribution into Maryland.</u></p> <p>d. Joseph Averino - Inquirer is requesting guidance regarding dispensing into Maryland: The inquiry below was initially sent to the Office of Health Care Quality, Maryland Department of Health, requesting the need for a Residential Service Agency License. They recommended that I follow up with the Board of Pharmacy. As background, Amber Specialty Pharmacy has brick and mortar locations in Nebraska and New York. Those pharmacies hold non-resident Maryland pharmacy licenses allowing us to serve the citizens of Maryland. There are two issues for your consideration: 1. If Amber Specialty Pharmacy dispenses, what is considered a percutaneous nerve field stimulator, to a Maryland resident, would this require additional licensure, other than a pharmacy license, in the state of Maryland? In most cases, the prescribed device would be dispensed to the prescribing health care</p>	<p>8d. Recommendation by committee; 2nd by K. Morgan.</p>	<p>The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>professional to provide to the patient. This item would be delivered via common carrier. 2. If Amber Specialty Pharmacy provides/dispenses infusion pumps, tubing and related supplies to a patient as part of infusion therapy, would this require additional licensure, other than a pharmacy license, in the state of Maryland? These items would be delivered via common carrier.</p> <p><u>Committee recommendation:</u> <u>Regarding scenario #1 If over 5% of annual sales a Distributor permit is needed. Regarding #2, only the pharmacy permit is needed</u></p> <p>e. Prescription Drug Monitoring Program - The Office of Provider Engagement and Regulation (OPER) is statutorily required to consult with the Technical Advisory Committee (TAC) to support the Prescription Drug Monitoring Program's (PDMP) quantitative data analysis and utilize their clinical expertise. According to Health General §21-2A-07, the TAC is responsible for providing clinical guidance and interpretation of PDMP data to identify possible violations of law or possible breaches of professional standards within PDMP data. The TAC consists of a voluntary group of nine providers including a pharmacist, as well as other providers. Dr. Nadeem Aslam currently fills the pharmacist seat. OPER is reaching out to the Maryland health licensing</p>	<p>8e. Recommendation by committee; 2nd by K. Morgan.</p>	<p>The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>boards requesting continuing education credits for TAC members' time and commitment to PDMP activities. Most TAC members contribute ~2 hours per quarter between meetings and review of PDMP data. OPER staff track TAC member participation and could offer documentation to the Board. The TAC serves an incredibly important role for the PDMP. The TAC ensures that prescribers receive clinically relevant information in the educational letters and helps the PDMP identify specific metrics that guides educational outreach. Would the Board of Pharmacy offer continuing education credits to relevant TAC members for their time and efforts supporting the PDMP?</p> <p><u>Committee recommendation: Under our current regulations we could not allow for CE's to be counted.</u></p> <p>f. Flywheel Healthcare Will the Board accept a NABP Supply Chain inspection in lieu of a VAWD inspection for a relocating Distributor? <u>Committee Recommendation: They do need an inspection; the Board can accept pending VAWD accreditation. Will be required to have a background check if staff has changed or results are not dated within the last 6 months.</u></p>	8f. Recommendation by committee; 2 nd by K. Morgan.	The Board voted to approve this motion.

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
C. Public Relations Committee	E. Yankellow, Commissioner	<p>Public Relations Committee Update:</p> <ul style="list-style-type: none"> The Committee did not meet in November, but they are moving forward with finalizing the virtual CE program. This will take place January 12 for 1 hour between 12pm-1pm. Don Taylor will have a segment on emergency preparedness. There will be a cut-off of 100 registrants and this information will be posted on the Board's website. 		
D. Disciplinary	J. Hardesty Chair	<p>Disciplinary Committee Update:</p> <ul style="list-style-type: none"> Committee met December 2 A confidential discussion will be held in the Board's Closed Public Session. 		
E. Emergency Preparedness Task Force	N. Leikach, Chair	<p>Emergency Preparedness Task Force Update:</p> <ul style="list-style-type: none"> Due to the email blast 300 pharmacist and technicians signed up with Maryland Responds. Emails will go out to those new volunteers as soon as possible. 		
IV. Other Business & FYI	K. Morgan, President	<ul style="list-style-type: none"> David Jones-is working on ASCP's Spring meeting to take place in mid-April. Aliyah Horton-Executive Director MPhA shared registration is open for the mid-year meeting Feb 21. There will be 6 CE's for the full day. A question was raised from the public regarding COVID-19 vaccination protocols established in the pharmacy. Ms. Speights- 		

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
V. Adjournment	K. Morgan, President	<p>Napata will provide follow-up information once received and it will be posted on the Board's website.</p> <p>A. The Public Meeting was adjourned at 10:37 am.</p> <p>B. K. Morgan convened a Closed Public Session to conduct a medical review committee evaluation of confidential applications.</p> <p>C. The Closed Public Session was adjourned. Immediately thereafter, K. Morgan, convened an Administrative Session for purposes of discussing confidential disciplinary cases.</p> <p>D. With the exception of cases requiring recusals, the Board members present at the Public Meeting continued to participate in the Closed Public Session and the Administrative Session</p>	Motion to close the Public Board Meeting by K. Evans 2 nd by K. Rusinko.	The Board voted to approve this motion.

PRESIDING OFFICER'S WRITTEN STATEMENT FOR CLOSING A MEETING ("CLOSING STATEMENT")
UNDER THE OPEN MEETINGS ACT (General Provisions Article § 3-305)

This form has two sides. Complete items 1 – 4:

1. Recorded vote to close the meeting: Date: 12/14/20 Time: 10:37; Location: Conference Call;
Motion to close meeting made by: K. Evans Seconded by R. Kusin ko;
Members in favor: Unanimous; Opposed: None;
Abstaining: —; Absent: —

2. Statutory authority to close session (check all provisions that apply):

This meeting will be closed under General Provisions Art. § 3-305(b) only:

(1)___ "To discuss the appointment, employment, assignment, promotion, discipline, demotion, compensation, removal, resignation, or performance evaluation of appointees, employees, or officials over whom this public body has jurisdiction; any other personnel matter that affects one or more specific individuals"; (2)___ "To protect the privacy or reputation of individuals concerning a matter not related to public business"; (3)___ "To consider the acquisition of real property for a public purpose and matters directly related thereto"; (4)___ "To consider a matter that concerns the proposal for a business or industrial organization to locate, expand, or remain in the State"; (5)___ "To consider the investment of public funds"; (6)___ "To consider the marketing of public securities"; (7)___ "To consult with counsel to obtain legal advice"; (8)___ "To consult with staff, consultants, or other individuals about pending or potential litigation"; (9)___ "To conduct collective bargaining negotiations or consider matters that relate to the negotiations"; (10)___ "To discuss public security, if the public body determines that public discussion would constitute a risk to the public or to public security, including: (i) the deployment of fire and police services and staff; and (ii) the development and implementation of emergency plans"; (11)___ "To prepare, administer, or grade a scholastic, licensing, or qualifying examination"; (12)___ "To conduct or discuss an investigative proceeding on actual or possible criminal conduct"; (13) "To comply with a specific constitutional, statutory, or judicially imposed requirement that prevents public disclosures about a particular proceeding or matter"; (14)___ "Before a contract is awarded or bids are opened, to discuss a matter directly related to a negotiating strategy or the contents of a bid or proposal, if public discussion or disclosure would adversely impact the ability of the public body to participate in the competitive bidding or proposal process."

Continued →

3. For each provision checked above, disclosure of the topic to be discussed and the public body's reason for discussing that topic in closed session.

Citation (insert # from above)	Topic	Reason for closed-session discussion of topic
§3-305(b) (3)	Application for licensure	To engage in medical review committee deliberations regarding confidential matters contained in applications
§3-305(b) ()		
§3-305(b) ()		
§3-305(b) ()		
§3-305(b) ()		

4. This statement is made by Deena Speights-Napata, Presiding Officer.
Deena Speights-Napata for Kevin Morgan

WORKSHEET FOR OPTIONAL USE IN CLOSED SESSION: INFORMATION THAT MUST BE DISCLOSED IN THE MINUTES OF THE NEXT OPEN MEETING

Time of closed session: 10:37am Place: Conference Call
 Purpose(s): To review confidential matters in license applications
 Members who voted to meet in closed session: unanimous
 Persons attending closed session: Anyone present in the open session
 Authority under § 3-305 for the closed session: 3-305(13)
 Topics actually discussed: Applications for licensing
 Actions taken: Process applications accordingly Each recorded vote: Affirmative majority vote each application

For a meeting recessed to perform an administrative function (§ 3-104): Time: 11:00
 Place: Conference Call Persons present: Persons in open Subject matter discussed: Complaint Investigations